Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective interventional trial that aims to restore iodine incorporation in
tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.